This study aims to evaluate the cost-utility of dimethyl fumarate (DMF) compared with teriflunomide (TFM) for relapsing multiple sclerosis (RMS) in China.
A Markov model was constructed based on a from healthcare system perspective in China over a 37-year horizon. Drug acquisition costs, monitoring costs, disease management costs, disease relapse costs and adverse events management costs were included. QALYs was used as the outcome. Utility of different model statuses and disutility caused by adverse events were also considered in the inputs. Costs and utility inputs were derived from published studies, public documents, and expert interviews. One-way sensitivity analysis (DSA) and probability sensitivity analysis (PSA) were conducted to evaluate the robustness of the results.
Over a 37-year time horizon, DMF led to an incremental QALY gain of 0.16 (4.10 of DMF and vs 3.94 of TFM) and reduced the total cost of ¥128,923 yuan (¥513,105 of DMF and vs ¥642,028 of TFM) compared with TFM. Cost savings are mainly drug acquisition costs, monitoring costs, disease management costs, disease relapse costs and adverse events management costs. DSA results showed that the disability progression hazard ratio values of TFM and DMF were the main drivers. PSA results showed a 100% probability of DMF being cost-effective compared to TFM at a threshold of 1 GDP per capita.
DMF dominates the TFM for the treatment of RMS from healthcare system perspective in China.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |